Volume 48, Number 7, 1386-1392, DOI: 10.1007/s00125-005-1791-6

Published in partnership with the

Logo

European Association for the Study of Diabetes

Activation of opioid μ-receptors by loperamide to improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells

T.-F. Tzeng, I.-M. Liu and J.-T. Cheng

View Related Documents

Abstract

Aims/hypothesis  

This study investigated the role of opioid mgr-receptor activation in the improvement of insulin resistance.

Methods  

Myoblast C2C12 cells were cultured with IL-6 to induce insulin resistance. Radioactive 2-deoxyglucose (2-DG) uptake was used to evaluate the effect of loperamide on insulin-stimulated glucose utilisation. Protein expression and phosphorylation in insulin-signalling pathways were detected by immunoblotting.

Results  

The insulin-stimulated 2-DG uptake was reduced by IL-6. Loperamide reversed this uptake, and the uptake was inhibited by blockade of opioid mgr-receptors. Insulin resistance induced by IL-6 was associated with impaired expression of the insulin receptor (IR), IR tyrosine autophosphorylation, IRS-1 protein content and IRS-1 tyrosine phosphorylation. Also, an attenuated p85 regulatory subunit of phosphatidylinositol 3-kinase, Akt serine phosphorylation and the protein of glucose transporter subtype 4 were observed in insulin resistance. Loperamide reversed IL-6-induced decrement of these insulin signals.

Conclusions/interpretation  

Opioid mgr-receptor activation may improve IL-6-induced insulin resistance through modulation of insulin signals to reverse the responsiveness of insulin. This provides a new target in the treatment of insulin resistance.

Keywords  C2C12 cells - IL-6 - Insulin resistance - Loperamide - Opioid mgr-receptors

Fulltext Preview

Image of the first page of the fulltext document